Literature DB >> 11204865

Diagnostic applications of cystatin C.

C H Reed1.   

Abstract

Cysteine proteases are proteolytic enzymes involved in many pathological processes and found in the lysosomes of cells; examples include the cathepsins B, H and L. The role of cysteine proteases is crucial in normal cellular metabolism, being fundamental to intracellular protein turnover, degradation of collagen, and cleaving of precursor proteins. Cysteine protease inhibitors, of which the cystatin superfamily are one example, constitute the final regulatory step in the control of cysteine proteases. Currently, cystatin C is the most frequently investigated family member and is involved in processes such as tumour invasion and metastasis, inflammatory processes and some neurological diseases. In such diseases the emphasis is placed on the fine balance and regulation of both the cysteine proteases and their inhibitors, with an imbalance resulting in a pathological state. In addition, the constant serum concentration of cystatin C means it has possible application as a replacement for creatinine in the measurement of glomerular filtration rate. To date, several assays have been developed and studies show a promising future for its use in the medical laboratory, and not just as a research tool. This review of cystatin C includes a brief history of its discovery and characterisation, provides a guide to some of the processes in which its role is fundamental, and highlights developments in its use as a clinical biomarker in the disease processes discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11204865

Source DB:  PubMed          Journal:  Br J Biomed Sci        ISSN: 0967-4845            Impact factor:   3.829


  16 in total

Review 1.  Commentary: clinical diagnostic use of cystatin C.

Authors:  Davis Massey
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

Review 2.  Cystatin superfamily.

Authors:  Josiah Ochieng; Gautam Chaudhuri
Journal:  J Health Care Poor Underserved       Date:  2010-02

Review 3.  Biomarkers of AAA progression. Part 1: extracellular matrix degeneration.

Authors:  Femke A M V I Hellenthal; Willem A Buurman; Will K W H Wodzig; Geert Willem H Schurink
Journal:  Nat Rev Cardiol       Date:  2009-05-26       Impact factor: 32.419

4.  Comparison of serum creatinine and serum cystatin C as biomarkers to detect sepsis-induced acute kidney injury and to predict mortality in CD-1 mice.

Authors:  Asada Leelahavanichkul; Ana Carolina P Souza; Jonathan M Street; Victor Hsu; Takayuki Tsuji; Kent Doi; Lingli Li; Xuzhen Hu; Hua Zhou; Parag Kumar; Jürgen Schnermann; Robert A Star; Peter S T Yuen
Journal:  Am J Physiol Renal Physiol       Date:  2014-08-20

5.  Serum levels of cystatin C in elderly lung cancer patients.

Authors:  Gen Ohara; Kunihiko Miyazaki; Koichi Kurishima; Katsunori Kagohashi; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Oncol Lett       Date:  2011-11-24       Impact factor: 2.967

6.  Autophagy: Many paths to the same end.

Authors:  Ana Maria Cuervo
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

7.  Application of cystatin C reduction ratio to high-flux hemodialysis as an alternative indicator of the clearance of middle molecules.

Authors:  Joon-Sung Park; Gheun-Ho Kim; Chong Myung Kang; Chang Hwa Lee
Journal:  Korean J Intern Med       Date:  2010-02-26       Impact factor: 3.165

8.  Clinical value of serum cystatin C by ELISA for estimation of glomerular filtration rate.

Authors:  Xunhui Xu; Jianzhou Zou; Xiaoqiang Ding; Dingguang Xin; Yushen Ren
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

9.  Serum levels of cystatin C in patients with malignancy.

Authors:  Keiko Nakai; Masayuki Kikuchi; Keiko Fujimoto; Yoshito Kaneko; So Omori; Kenji Nakai; Akira Suwabe
Journal:  Clin Exp Nephrol       Date:  2008-03-05       Impact factor: 2.801

10.  Targeted quantitative mass spectrometric immunoassay for human protein variants.

Authors:  Olgica Trenchevska; Dobrin Nedelkov
Journal:  Proteome Sci       Date:  2011-04-08       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.